Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?

AbbVie reported positive results from a Phase 3 trial of QULIPTA for migraine treatment. The trial met its primary endpoint, according to the company. This news may impact investor sentiment toward AbbVie's pipeline and growth prospects.

Nxera Pharma has signed a $1.47bn global licensing deal with AbbVie for NXE0033744, an IBD treatment. Nxera receives $100m upfront and potential milestone payments. The deal is subject to antitrust clearances. NXE0033744 targets unmet needs in IBD with a novel mechanism. AbbVie gains exclusive rights to develop and commercialize the drug.

J&J and Protagonist's Icotyde showed improvement in psoriatic arthritis in a Phase 3 trial, with 58% of patients achieving a 20% improvement in disease activity. However, analysts at BMO Capital Markets noted that the results fell short of AbbVie's Skyrizi, which has a 23% placebo-adjusted improvement. Skyrizi's stronger efficacy and dosing schedule may give it an edge, but Icotyde's oral administration could appeal to patients who prefer to avoid injections.

AbbVie ABBV reported that patients using GLP-1 weight-loss drugs showed improved facial satisfaction in two studies by its Allergan Aesthetics division. The studies, presented at a dermatology conference, involved 30 and 25 patients respectively, who received treatments like hyaluronic acid fillers and Botox. Participants reported significant improvements in facial appearance satisfaction and skin quality.

AbbVie (ABBV) reported that patients using GLP-1 weight-loss drugs showed improved facial satisfaction post-cosmetic treatments in two studies by its Allergan Aesthetics division, according to the company. The results were presented at a dermatologic surgery conference.

AbbVie (ABBV) stock rose 38.4% in the past year, near its 52-week high. Management warned of a 2027 pricing pressure on Vraylar due to U.S. drug law, citing Imbruvica's 26.1% sales drop in Q3 2026 from similar pricing. Vraylar sales grew 14.3% in Q3 2026 to $1.1B. Botox's IRA status is uncertain, with a court ruling in AbbVie's favor but potential government appeal. Vraylar contributed 5.9% of 2025 revenue, with 2026 sales expected at $4.2B.